Piramal Pharma supports Women’s Wellbeing with the launch of its i-pill Daily Awareness Initiative
Piramal Consumer Healthcare has launched a new campaign for its i-pill Daily product, which aims to promote women’s health, dignity, and informed choice. The campaign highlights the importance of choosing the right brand, especially in a category where substitution is common and purchases are often made with hesitation. The goal is to encourage consumers to ask boldly, insist clearly, and choose confidently, rather than settling for a substitute due to discomfort or haste.
The campaign is set in a black-and-white style and aims to tackle the barrier of lack of insistence on the right brand at the moment of purchase. The film cleverly draws attention to the outdated discomfort surrounding the buying experience and flips the narrative by urging viewers to ask questions, assert their agency, and choose a trusted brand like i-pill Daily.
According to Nandini Piramal, Chairperson of Piramal Pharma Limited, every woman deserves access to healthcare that is safe, reliable, and respectful of her choices. The campaign reminds women that their health is too important to be left to chance or compromise and encourages them to choose what’s best for them.
Menaka Menon, President and Managing Partner of DDB Mudra Group, commented that the campaign aims to tackle the problem of consumers ending up with a substitute product due to social conditioning and embarrassment around the purchase of a contraceptive product. The campaign plays up the shift in society towards women exercising their discretion and choice, and contrasts it with the meek acceptance typically associated with such decisions in the past.
The campaign is backed by Piramal Pharma’s strong record in women’s wellness and is recognized as one of India’s Most Trusted Brands by Marksmen. It marks a strategic shift from generic awareness to informed, quality-first decisions. The film will be supported across digital platforms, including YouTube and Instagram, and will be amplified on television in select priority markets.
Overall, the campaign aims to empower women to make informed choices about their reproductive health and to choose a trusted brand like i-pill Daily. By encouraging consumers to ask boldly and insist clearly, the campaign hopes to reverse the trend of substitution and promote a culture of confidence and assertiveness around women’s health.
Glenmark Pharmaceuticals Sees Significant Profit Increase in March 2025 Despite Elevated Interest Expenses – MarketsMojo
Glenmark Pharmaceuticals has announced its financial results for the fourth quarter and full year ended March 2025, highlighting a solid profit growth despite increasing interest costs. The company’s performance was driven by robust sales across its key markets and a strong product pipeline.
Revenue for the quarter ended March 2025 stood at ₹3,483.6 crore, representing a 13.4% year-over-year (YoY) growth. For the full year, revenue was ₹12,853.1 crore, up 12.1% YoY. The company’s operating profit (EBITDA) for the quarter was ₹731.4 crore, with a margin of 21%, while full-year EBITDA reached ₹2,631.4 crore.
Net profit for the quarter ended March 2025 was ₹356.2 crore, a significant increase of 25.5% YoY. However, the company’s interest costs rose to ₹133.8 crore during the quarter, up from ₹93.8 crore in the same period last year. This increase was primarily due to higher borrowing costs and an expansion of the company’s debt.
Glenmark’s formulations business, which accounts for the majority of its revenue, grew 14.1% YoY in the fourth quarter, driven by strong sales in the United States, Europe, and India. The company’s US business, in particular, showed significant growth, with revenue increasing by 23.1% YoY.
The company’s research and development (R&D) expenses for the quarter were ₹245.8 crore, representing 7.1% of revenue. Glenmark has a strong pipeline of products under development, with several new drug applications (NDAs) and abbreviated new drug applications (ANDAs) filed in various markets.
Glenmark’s management expressed confidence in the company’s growth prospects, citing a robust product pipeline, expanding global presence, and a strong balance sheet. The company is focused on investing in R&D and expanding its presence in emerging markets to drive long-term growth.
Overall, Glenmark Pharmaceuticals’ fourth-quarter and full-year results demonstrated the company’s ability to deliver strong profit growth despite rising interest costs. With a solid product pipeline and expanding global presence, the company is well-positioned for long-term success in the pharmaceutical industry. As the company continues to invest in R&D and expand its presence in emerging markets, investors will be closely watching its future performance to assess the sustainability of its growth trajectory.
Lupin and Honeywell Collaborate to Develop Eco-Friendly Inhaler Solutions with Innovative Propellant Technology.
Lupin Limited, a leading pharmaceutical company, has partnered with Honeywell to integrate the Solstice Air propellant into its next-generation inhalers for respiratory care. This collaboration aims to enhance treatment for patients with asthma and chronic obstructive pulmonary disease (COPD) while reducing the environmental impact of inhaler technologies. Solstice Air is a non-flammable propellant that offers a more environmentally friendly alternative to traditional hydrofluorocarbon (HFC)-based options, decreasing greenhouse gas emissions by up to 99.9%.
Lupin plans to become the first pharmaceutical company in India to use Solstice Air as a large-scale propellant in pressurized metered-dose inhalers (pMDIs). This move aligns with the company’s commitment to minimizing its carbon footprint while delivering effective care to patients. Vinita Gupta, CEO of Lupin, emphasized the company’s dedication to providing high-quality treatments while ensuring a healthier and more sustainable future for patients and communities globally.
The partnership with Honeywell reflects Lupin’s focus on advancing sustainable healthcare solutions. Ashish Modi, President of Honeywell India, highlighted the importance of Solstice Air in delivering safe and effective treatments while minimizing harmful greenhouse gas emissions. The companies are currently negotiating the details of the partnership, with the goal of finalizing the terms soon.
Lupin Limited is a major player in the global pharmaceutical industry, with a strong presence in therapy areas such as respiratory care, cardiovascular, and anti-diabetic treatments. The company operates 15 manufacturing facilities and seven research centers globally, employing over 23,000 professionals. Honeywell, a global leader in technology and innovation, is committed to addressing complex challenges through its cutting-edge solutions, enhancing safety, security, and sustainability worldwide.
The integration of Solstice Air into Lupin’s inhalers is expected to significantly reduce the environmental impact of respiratory treatments. With this partnership, Lupin and Honeywell are taking a major step towards advancing sustainable healthcare solutions and reducing carbon emissions. The collaboration demonstrates the companies’ shared commitment to providing effective treatments while promoting environmentally responsible practices. By adopting innovative technologies like Solstice Air, Lupin is poised to make a positive impact on the environment and improve patient health outcomes.
Biocon Secures Six-Month Extension on Insulin Supply Contract with Ministry of Health
The Malaysian government has extended its insulin supply contract with India’s Biocon Biologics for an additional six months, from April 29 to October 28. The original 36-month contract, which began in 2022 and was set to expire in April 2025, was between the Ministry of Health (MOH), Biocon’s Malaysian subsidiary Biocon Sdn Bhd, and Duopharma Marketing Sdn Bhd (DMktg). Biocon Biologics has been the Ministry of Health’s partner of choice for insulin requirements for nearly 10 years, manufacturing a range of recombinant human insulin products at its facility in Johor, Malaysia.
The company’s insulin products are distributed in Malaysia through its commercial partner DMktg. Biocon Biologics is committed to providing affordable access to life-saving insulins to people with diabetes in Malaysia and globally. The company’s facility in Malaysia not only supplies the domestic market but also exports insulin to the global market. The facility has received approvals from several regulatory agencies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
In 2022, the company faced criticism from the Health Minister, Dzulkefly Ahmad, who blamed Biocon for failing to meet its contractual obligations, resulting in an unprecedented insulin shortage. However, the company has continued to work with the Ministry of Health to ensure a stable supply of insulin to patients in Malaysia. The extension of the contract is a testament to the company’s commitment to providing affordable and accessible insulin to those who need it. With its state-of-the-art facility in Johor, Biocon Biologics is well-positioned to meet the growing demand for insulin in Malaysia and globally.
The company’s commitment to affordable access to insulin is critical, given the growing prevalence of diabetes in Malaysia. According to the International Diabetes Federation, Malaysia has one of the highest prevalence rates of diabetes in the world, with over 3.5 million people living with the condition. Biocon Biologics’ efforts to provide affordable insulin will help to improve healthcare outcomes for these individuals and reduce the burden of diabetes on the healthcare system. Overall, the extension of the contract between the Malaysian government and Biocon Biologics is a positive development for patients with diabetes in Malaysia and reflects the company’s ongoing commitment to providing affordable and accessible healthcare solutions.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.